Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Emetine

$400

  • Brand : BIOFRON

  • Catalogue Number : BN-O1857

  • Specification : 98%(HPLC)

  • CAS number : 483-18-1

  • Formula : C29H40N2O4

  • Molecular Weight : 480.6

  • PUBCHEM ID : 10219

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1857

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

480.6

Appearance

Botanical Source

Structure Type

Category

SMILES

Synonyms

IUPAC Name

(2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine

Applications

Density

1.17g/cm3

Solubility

Flash Point

316.9ºC

Boiling Point

600.3ºC at 760mmHg

Melting Point

89-96ºC

InChl

InChl Key

AUVVAXYIELKVAI-CKBKHPSWSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:483-18-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

32545799

Abstract

As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.

KEYWORDS

antiviral drug combinations; antivirals; broad-spectrum antivirals.

Title

Potential Antiviral Options against SARS-CoV-2 Infection

Author

Aleksandr Ianevski 1, Rouan Yao 1, Mona Høysæter Fenstad 2 3, Svetlana Biza 1, Eva Zusinaite 4, Tuuli Reisberg 5, Hilde Lysvand 1, Kirsti Løseth 1, Veslemøy Malm Landsem 1, Janne Fossum Malmring 2, Valentyn Oksenych 1, Sten Even Erlandsen 1, Per Arne Aas 1, Lars Hagen 1, Caroline H Pettersen 1, Tanel Tenson 4, Jan Egil Afset 1 2, Svein Arne Nordbø 1 2, Magnar Bjøras 1, Denis E Kainov 1 4

Publish date

2020 Jun 13;

PMID

32438034

Title

Does lopinavir really inhibit SARS-CoV-2?

Author

Dario Cattaneo 1, Dario Cattaneo 2, Cristina Gervasoni 3, Mario Corbellino 4, Massimo Galli 4, Agostino Riva 4, Cristina Gervasoni 4, Emilio Clementi 5, Emilio Clementi 6

Publish date

2020 Aug

PMID

32251767

Abstract

An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.

KEYWORDS

ABSTRACT; COVID-19; Emetine; Homoharringtonine; Lopinavir; Remdesivir; Ritonavir.

Title

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Author

Ka-Tim Choy 1, Alvina Yin-Lam Wong 1, Prathanporn Kaewpreedee 1, Sin Fun Sia 1, Dongdong Chen 1, Kenrie Pui Yan Hui 1, Daniel Ka Wing Chu 1, Michael Chi Wai Chan 1, Peter Pak-Hang Cheung 2, Xuhui Huang 2, Malik Peiris 1, Hui-Ling Yen 3

Publish date

2020 Jun;